Zydus Lifescience Q4 Result: Pharmaceutical firm Zydus Lifesciences announced on Monday, May 20, that it had a consolidated net profit of Rs 1,171 crore for the March quarter of FY25, down from Rs 1,823 crore in the same period last year. While the dip in bottomline was due to a high base last year, the company’s operating performance was resilient across important verticals.
The company recorded revenue from operations growth of 18 per cent year-on-year to Rs 6,528 crore as compared to Rs 5,533 crore in Q4 FY24.
EBITDA came at Rs 2,126 crore, growing at 30.3 per cent from Rs 1,630.5 crore in the year-ago period. EBITDA margin sharply improved to 32.6 per cent as compared to 29.5 per cent last year, highlighting the company’s improvements in cost efficiencies and product mix.
Board recommends Rs 11 final dividend
Zydus has proposed a final dividend of Rs 11 per equity share of face value Rs 1 which will be paid after approval from the shareholders at the Annual General Meeting set for August 12, 2025.
Zydus Lifesciences has announced a final dividend of Rs 11 per share for FY25, its highest-ever in over a decade, making headlines on Dalal Street. The dividend recommendation was approved by the board along with the Q4 earnings declaration on May 20, 2025.
This marks a sharp jump from last year’s final dividend of Rs 6 per share and is nearly three times higher than the Rs 3 dividend paid in FY24. Over the past ten years, Zydus had mostly maintained payouts in the range of Rs 2.50–Rs 6, making this year’s announcement a standout.
The stock may gain attention in the coming sessions, given the dividend yield and payout jump, especially among long-term investors hunting for value in pharma stocks.
Dividend history at a glance:
Performance
The India-branded formulations segment remained the clear outperformer in the portfolio, with double-digit growth, ahead of growth of the market overall. The consumer wellness vertical also maintained strong momentum with sizeable volume-led increases.
The company generated revenues of Rs 3,130.7 crore from its US business, representing year-on-year growth of 24 per cent, which Zydus attributed to volume ramp-up and new product launches.
Zydus’s international markets business achieved double-digit growth, especially from demand across geographies, while API segment revenues decreased 10 per cent to Rs 129 crore in the quarter reviewed.
Stock Reaction
Despite the healthy topline and margin expansion, Zydus Lifesciences shares dropped 2.98 per cent to Rs 884.1 each on the NSE right after the results announcement, driven by profit booking from investors, after a recent rally.
Moving forward, analysts will anticipate the company comments on product launches and regulatory clearances for the US market.
